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Hantavirus 
Outbreak, 
Germany, 2007
To the Editor: Hantavirus disease 
(for review see [1]) has been report-
able in Germany since 2001, accord-
ing to the Federal Infection Protection 
Act. In this country, Puumala virus 
(PUUV) causes most clinical hantavi-
rus cases, although Dobrava-Belgrade 
virus and Tula virus also circulate (1). 
From 2001 through 2006, an aver-
age of ≈220 cases were reported per 
year (incidence 0.267/100,000) with 
a maximum of 448 cases in 2005. In 
contrast, 1,687 cases were reported in 
2007 (2). Whereas in 2005 the highest 
incidence of infection was in metro-
politan areas (3), the current outbreak 
is focused in the rural areas in southern 
and western Germany. Clinical case-
patients exhibit key characteristics of 
hantavirus disease (nephropathia epi-
demica): acute high fever; pain in the 
back, head, and/or abdomen; protei-
nuria; rise of serum creatinine; throm-
bocytopenia; and renal failure (1). 
The outbreak provided considerable 
numbers of clinical samples from the 
viremic phase and thus has enabled a 
molecular epidemiologic analysis of 
the circulating virus.
At the National Consultation Lab-
oratory for Hantavirus Infections (Ber-
lin), we received early-phase serum 
specimens from the outbreak regions 
for confi rmation assays. In enzyme 
immunoassays and Western blot tests 
(4), 80 samples from patients during 
the early clinical phase were positive 
for PUUV-specifi c immunoglobulin 
(Ig) M antibodies. All IgM data were 
accompanied by simultaneous or sub-
sequent detection of PUUV-specifi c 
IgG. The samples were screened for 
hantavirus RNA by reverse transcrip-
tion–PCR (RT-PCR) (5). Of the 80 
early-phase serum samples, 42 (53%) 
were RT-PCR positive. For a subset 
of 14 of the 42 samples, a 557-nt seg-
ment of the nucleocapsid (S) gene un-
derwent nucleotide sequence analysis 
as described previously (6).
The Figure, panel A, shows a 
map of Germany with the residences 
of those patients from whom virus 
sequences were amplifi ed (marked 
by letter H in front of the specimen 
number). In the phylogenetic analy-
sis, despite a substantial evolutionary 
distance to PUUV strains from other 
parts of Europe, the virus sequences 
unambiguously grouped within the 
PUUV species (Figure, panel B). The 
few previously known human PUUV 
sequences from individual clinical 
case-patients in Germany, “Berkel” 
from Munsterland (7) and “Heidel-
berg” from a region located between 
Swabian Jura and Spessart Forest 
(8), as well as human-derived strains 
from a small 2004 outbreak in the 
Bavarian Forest (6), were included 
in this analysis. The results showed a 
clustering of the new viral sequences 
strictly according to residential areas 
of the patients, forming the following 
4 clades: Swabian Jura (SJ), Spessart 
Forest (SF), Munsterland (ML), and 
Bavarian Forest (BF). Two different 
single sequences, Karlsruhe (from a 
region in northwestern Swabian Jura) 
and Essen (in southern Munster-
land), represent 2 putative additional 
lineages.
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Most sequences in this study 
were obtained from Swabian Jura, 
the region with the highest ill-
ness rate of the outbreak (incidence 
32.9/100,000). The Swabian Jura was 
previously identifi ed as a hantavirus-
endemic area characterized by higher 
seroprevalence rates in the population 
compared with the rest of Germany 
(9). Sequence alignments within this 
clade showed a nucleotide sequence 
diversity of up to 5.5%. Within the 
BF clade, the diversity is up to 4%. 
However, between the 4 phylogenetic 
clades mentioned above (SJ, SF, ML, 
and BF), a sequence variability of 
12%–18% was found.
The natural reservoir of PUUV is 
the bank vole, Myodes glareolus; the 
virus is transmitted to humans by the 
aerosolized excreta of these rodents 
(1). Sequence comparisons showed a 
tight correlation between human- and 
rodent-derived PUUV sequences ob-
tained from the same regional prove-
nance (nucleotide identity >98%) and 
high variability of sequences originat-
ing from different geographic regions 
(nucleotide identity ≈85%). Neighbor-
joining analyses confi rmed the direct 
clustering of human- and rodent-de-
rived sequences in the different phylo-
genetic clades (Figure, panel B).
In this study we focused on the 
analysis of a 557-nt S-segment region. 
For more detailed studies, analysis of 
the complete S and M sequences of the 
virus strains will be necessary. Never-
theless, our results demonstrate a high 
variability among the German PUUV 
strains but a strong clustering of viral 
sequences of human and rodent origin 
in the same geographic region. The di-
versity of the PUUV clusters suggests 
their separate evolutionary history in 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008 851 
Figure. A) Map of Germany showing origins of viral sequences from the 2007 outbreak. H, sequences of human origin; M, sequences 
of rodent origin (Myodes glareolus). Dotted circles mark the outbreak regions characterized by particular virus sequence clusters; SJ, 
Swabian Jura; BF, Bavarian Forest; SF, Spessart Forest; ML, Munsterland. B) Neighbor-joining phylogenetic tree (TN93 evolutionary 
model) of European Puumala virus (PUUV) strains based on partial sequences of the S segment (557 nt, position 385–941). Bootstrap 
values >70%, calculated from 10,000 replicates, are shown at the tree branches. PUUV-like sequences from Japan (JPN) were used 
as an outgroup. Sequences taken from GenBank are indicated by their accession numbers. New sequences from this study are given 
in boldface. Accession numbers of new sequences are H101, EU266757; H233, EU266758; H99, EU266759; M42, EU085563; M50, 
EU085565 ; H145, EU266760; H85, EU266761; M4, EU266762; H81, EU266763; H232, EU266764; H231, EU266765; M13, EU085558; 
H72, EU266766; H290, EU266767; M104, EU246963; H127, EU266768; M837, EU266769; H208, EU266770; H303, EU266771; H68, 
EU266772. For clarity, previously characterized PUUV clades from other parts of Europe are shown in simplifi ed form. However, the 
complete dataset of PUUV sequences as presented by Schilling et al. (6) was used to calculate the tree. Previously defi ned lineages 
are indicated by abbreviated names: AUT, Austrian; BAL, Balkan; BALT, Baltic; DAN, Danish; FIN, Finnish; NSCA, North Scandinavian; 
OMSK, Russian from Omsk region; RUS, Russian; SSCA, South Scandinavian. Scale bar indicates an evolutionary distance of 0.1 
substitutions per position.
LETTERS
the different regions of Germany. In 
contrast, within these particular geo-
graphic areas, only slight sequence 
differences were found in longitudi-
nal analysis over several years. This 
conclusion is supported by the novel 
human Waldkirchen sequence (H72), 
which is almost identical to the BF 
strains from 2004 (6,10) and the 
similarity of newly derived human 
sequences from Munsterland (H208, 
H303) to the Berkel strain from 1994 
(7). The molecular characterization 
of the viral sequences of patient and 
rodent origin from the outbreak areas 
demonstrates that PUUV is the caus-
ative agent of the current outbreak.
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Chikungunya 
Virus in Aedes 
albopictus, Italy  
To the Editor: Chikungunya vi-
rus (CHIKV) infection is a self-lim-
iting illness characterized by fever, 
headache, weakness, rash, and arth-
ralgia. Some patients show prolonged 
weakness or arthralgia lasting several 
months. In 2006, several Indian Ocean 
states and India experienced outbreaks 
of CHIKV infection, where the vector 
was postulated to be Aedes albopictus 
in at least some areas (1,2). 
Starting from mid July 2007, in 2 
villages in Ravenna Province in Italy, 
Castiglione di Ravenna (≈1,700 in-
habitants) and Castiglione di Cervia 
(≈2,000 inhabitants), several residents 
sought treatment at local hospitals 
and health centers for high fever and 
arthralgia, joint and muscular pain, 
severe headaches, body aches, and in 
some cases, rash. Since the beginning 
of August 2007, an increasing num-
ber of febrile syndromes associated 
with arthralgia have been recorded 
among the residents of the area. By 
the end of August, the number of sick 
persons had increased to ≈150 (3). 
At the beginning of September, the 
disease was confi rmed as chikungu-
nya fever by the Superior Institute of 
Health (4).
On August 21 and 22, 2007, an 
entomologic investigation was carried 
out in the area. Ae. albopictus (215 
females and 57 males), Culex pipiens 
(369 females and 15 males), and a few 
specimens of Ae. caspius (5 females) 
and Anopheles spp. (2 females) were 
collected by using 3 light traps with-
out CO2 (Centers for Disease Control 
and Prevention [CDC], Atlanta, GA, 
USA) and 8 CO2-baited traps (similar 
to the CDC light trap) activated once 
overnight. Collections were obtained 
by using 2 small-handled aspirators 
per day of sampling. Collected mos-
quitoes were divided by species and 
pooled as described in the Table. 
852 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008
